Basis of Presentation and Significant Accounting Policies - Narrative (Details)	1 Months Ended						3 Months Ended		6 Months Ended		85 Months Ended
	Apr. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2019 USD ($)	Oct. 31, 2017 USD ($)	May 31, 2017 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) segment	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Oct. 31, 2018	Sep. 30, 2018
Accumulated deficit							$ 235,830,321		$ 235,830,321		$ 235,830,321	$ 209,153,659
Net loss							13,961,702	$ 6,937,910	26,856,837	$ 15,127,708
Cash, cash equivalents and short term investments							18,600,000		18,600,000		18,600,000
Derivative warrant liability							0		$ 0		0
Number of operating segments | segment									1
Unrecognized tax benefit							1,500,000		$ 1,500,000		1,500,000
Revenue							657,778	50,981	1,423,678	263,399
Customer deposits							2,700,000		2,700,000		2,700,000
Land option agreements							500,000		500,000		500,000
Other liabilities							$ 1,002,904		$ 1,002,904		$ 1,002,904
Shattuck
License fee received						$ 50,000
Initial license fees received						50,000
Proceeds from milestone payment		$ 100,000
Pelican Therapeutics, Inc.
Ownership interest in subsidiary							85.00%		85.00%		85.00%	85.00%	85.00%	80.00%
Pelican Therapeutics, Inc. | Grant and contract revenue
Revenue	$ 1,500,000						$ 0	$ 0.0	$ 0	$ 200,000	$ 15,200,000
Remaining grant amount receivable	$ 1,500,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Tranche 1
Revenue					$ 1,800,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Tranche 2
Revenue				$ 6,500,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Tranche 3
Revenue			$ 5,400,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Maximum
Amount awarded from CPRIT grant						$ 15,200,000
Elusys Therapeutics
Indemnification asset							$ 1,000,000.0		$ 1,000,000.0		$ 1,000,000.0